Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells-Reference-Cited by-同舟云学术

Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells

Published:2021-09-27 Issue:11 Volume:5 Page:1288-1305
ISSN:2157-846X
Container-title:Nature Biomedical Engineering
language:en
Short-container-title:Nat Biomed Eng

Author:

Zhang Bo^ORCID,Sun Jiaqi,Wang Yan,Ji Dezhong,Yuan Yeshuang,Li Shengjie,Sun Yeting,Hou Yingqin,Li Pengchong^ORCID,Zhao Lidan,Yu Fei,Ma Wenxiao^ORCID,Cheng Boyang,Wu Ling,Hu Jin,Wang Min,Song Wei,Li Xiaogang,Li Hao,Fei Yunyun,Chen Hua,Zhang Lihe,Tsokos George C.^ORCID,Zhou Demin^ORCID,Zhang Xuan^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Computer Science Applications,Biomedical Engineering,Medicine (miscellaneous),Bioengineering,Biotechnology

Link

https://www.nature.com/articles/s41551-021-00797-8.pdf

Reference58 articles.

1. Klatzmann, D. & Abbas, A. K. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat. Rev. Immunol. 15, 283–294 (2015).

2. Abbas, A. K., Trotta, E., Simeonov, R. D., Marson, A. & Bluestone, J. A. Revisiting IL-2: biology and therapeutic prospects. Sci. Immunol. https://doi.org/10.1126/sciimmunol.aat1482 (2018).

3. Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12, 180–190 (2012).

4. He, J. et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 79, 141–149 (2020).

5. Rosenzwajg, M. et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann. Rheum. Dis. 78, 209–217 (2019).

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Directed disruption of IL2 aggregation sites produces designer biologics with enhanced specificity coupled to improved production capacity;2024-09-03

2. RNA nanotherapeutics with fibrosis overexpression and retention for MASH treatment;Nature Communications;2024-08-27

3. The JAK-STAT pathway: from structural biology to cytokine engineering;Signal Transduction and Targeted Therapy;2024-08-21

4. Probing the Topological Effects on Stability Enhancement and Therapeutic Performance of Protein Bioconjugates: Tadpole, Macrocycle versus Figure‐of‐Eight;Advanced Healthcare Materials;2024-08

5. Extracellular Matrix‐Surrogate Advanced Functional Composite Biomaterials for Tissue Repair and Regeneration;Advanced Healthcare Materials;2024-07-22